CiToxLAB North America acquires new facility in Canada to expand bioanalysis and biomarker services
The CRO, CiToxLab (Misery, France), has acquired a new facility in Montreal, Canada, which will focus on bioanalysis and biomarker services to keep up with demand. The new laboratory will aid preclinical and clinical programs being dedicated to small and large molecule bioanalysis using techniques such as LC–MS, ligand binding assays and flow cytometry.
Jean-François Le Bigot, Chairman and CEO of CiToxLAB commented: “This expansion is the result of successful partnerships with our clients. It reinforces CiToxLAB’s commitment to enhancing the way we serve our customers. The relocation of some of our laboratory operations to this new building will free up areas in the main building, allowing us to increase our animal room capacity, resulting in shorter lead times for our clients.”
Andrew Graham, Site Manager at CiToxLAB North America, concluded: “We currently partner with eight of the top ten global pharmaceutical companies and about 200 biotech companies; we work with these customers at a very early stage on the development of their drug candidates, performing pharmacology and safety studies. These studies include bioanalysis and biomarkers investigations for which, in many cases, we have developed and validated the methods, often specific to their compounds.
“In that context, more and more customers consider it appropriate to continue working with us during the initial clinical trials in order to save time and money, and to avoid the added risk related to the transfer of methods between labs. The new building we have just purchased will allow us to better meet the increasing needs of our clients for a one-stop-shop CRO in laboratory sciences investigations.”
